Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Duchenne Muscular Dystrophy Pipeline Drugs Market Report Overview
Duchenne Muscular Dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects.
Key Targets in the Duchenne Muscular Dystrophy Pipeline Market
The key targets in the Duchenne Muscular Dystrophy pipeline market are Dystrophin, Utrophin, Androgen Receptor, Glucocorticoid Receptor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Connective Tissue Growth Factor, and Growth/Differentiation Factor 8. Dystrophin has the highest pipeline products.
Duchenne Muscular Dystrophy Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Duchenne Muscular Dystrophy Pipeline Market
The key MoA in the Duchenne Muscular Dystrophy pipeline market are Dystrophin Activator, Utrophin Activator, Glucocorticoid Receptor Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Androgen Receptor Agonist, Connective Tissue Growth Factor Inhibitor, and Growth/Differentiation Factor 8 Inhibitor. Dystrophin Activator has the highest pipeline products.
Duchenne Muscular Dystrophy Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Duchenne Muscular Dystrophy Pipeline Market
The key RoA in the Duchenne Muscular Dystrophy pipeline market are oral, intravenous, subcutaneous, parenteral, inhalational, intramuscular, intracoronary, intrathecal, intravascular, ophthalmic, and topical. Oral has the highest number of pipeline products.
Duchenne Muscular Dystrophy Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Type in the Duchenne Muscular Dystrophy Pipeline Market
The key molecule type in the Duchenne Muscular Dystrophy pipeline market are small molecule, antisense oligonucleotide, gene therapy, cell therapy, oligonucleotide, monoclonal antibody conjugated, recombinant protein, synthetic peptide, fusion protein, gene-modified cell therapy, monoclonal antibody, protein, antisense RNAI oligonucleotide, and biologic. Small molecule has the highest pipeline products.
Duchenne Muscular Dystrophy Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Duchenne Muscular Dystrophy Pipeline Market
The key companies in the Duchenne Muscular Dystrophy pipeline market are Sarepta Therapeutics Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, NS Pharma Inc, Avidity Biosciences Inc, Nippon Shinyaku Co Ltd, Pepgen Ltd, and Sarcomed AB. Sarepta Therapeutics Inc has the highest number of pipeline products.
Avidity Biosciences Inc: Avidity Biosciences Inc (Avidity Biosciences), formerly Avidity NanoMedicines LLC is a biotech company that develops antibody oligonucleotide conjugates (AOCs). Its proprietary platform technology has enhanced pharmacokinetic and biodistribution properties that improve the delivery of multiple therapeutic oligonucleotides. Its pipeline of therapeutic programs is intended for the treatment of rare muscle disorders and other serious diseases, including Duchenne muscular dystrophy, myotonic dystrophy, and muscle atrophy. The company has research collaborations with leading pharma companies, to discover antibody-based drug candidates against various therapeutic targets. Avidity Biosciences is headquartered in San Diego, California, the US.
Duchenne Muscular Dystrophy Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
Key targets | Dystrophin, Utrophin, Androgen Receptor, Glucocorticoid Receptor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Connective Tissue Growth Factor, and Growth/Differentiation Factor 8 |
Key MoA | Dystrophin Activator, Utrophin Activator, Glucocorticoid Receptor Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Androgen Receptor Agonist, Connective Tissue Growth Factor Inhibitor, and Growth/Differentiation Factor 8 Inhibitor |
Key RoA | Oral, Intravenous, Subcutaneous, Parenteral, Inhalational, Intramuscular, Intracoronary, Intrathecal, Intravascular, Ophthalmic, and Topical |
Key molecule types | Small Molecule, Antisense Oligonucleotide, Gene Therapy, Cell Therapy, Oligonucleotide, Monoclonal Antibody Conjugated, Recombinant Protein, Synthetic Peptide, Fusion Protein, Gene-Modified Cell Therapy, Monoclonal Antibody, Protein, Antisense RNAI Oligonucleotide, and Biologic |
Key companies | Sarepta Therapeutics Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, NS Pharma Inc, Avidity Biosciences Inc, Nippon Shinyaku Co Ltd, Pepgen Ltd, and Sarcomed AB |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Alpha Anomeric
American CryoStem Corp
Anagenesis Biotechnologies SAS
Antisense Therapeutics Ltd
ARMGO Pharma Inc
Astria Therapeutics Inc
AUM LifeTech Inc
Autotac Bio Inc
Avidity Biosciences Inc
Axolo Pharma Inc
Bayer AG
Biogen Inc
BioIncept LLC
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SA
CANbridge Life Sciences Ltd
Capricor Therapeutics Inc
Chengdu Fanxi Biopharma Co Ltd
Code Biotherapeutics Inc
Consortium.AI
Constant Therapeutics LLC
CRISPR Therapeutics AG
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DepYmed Inc
DMD Therapeutics Inc
DTx Pharma Inc
Dyne Therapeutics Inc
Dystrogen Therapeutics SA
Edgewise Therapeutics Inc
Editas Medicine Inc
Eli Lilly and Co
Eloxx Pharmaceuticals Inc
Encell Co Ltd
Entrada Therapeutics Inc
Epirium Bio Inc
EryDel SpA
Evox Therapeutics Ltd
FibroGen Inc
FibroGenesis LLC
Fulcrum Therapeutics Inc
InnoBioscience LLC
Italfarmaco SpA
Ixchel Pharma LLC
J2H Biotech
Keros Therapeutics Inc
KSbitugen Co Ltd
LambdaGen Therapeutics
Ludi Therapeutics
Milo Biotechnology LLC
Mitobridge Inc
Mitochon Pharmaceuticals Inc
MitoRx Therapeutics Ltd
MyoGene Bio LLC
Myos Inc
Myosana Therapeutics Inc
MyoTherix Inc
Nippon Shinyaku Co Ltd
NS Pharma Inc
OliPass Corporation
OMEICOS Therapeutics GmbH
Oncocross Co Ltd
Oncotelic Inc
Pepgen Ltd
PeptiDream Inc
Pfizer Inc
Pharmaxis Ltd
PhaseBio Pharmaceuticals Inc
Pliant Therapeutics Inc
Progenitor Therapeutics Ltd
Prothelia Inc
PTC Therapeutics Inc
PYC Therapeutics Ltd
RASRx LLC
RegenxBio Inc
ReoStem LLC
Ridgeline Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Satellos Bioscience Inc
Solid Biosciences Inc
Stealth BioTherapeutics Corp
SteroTherapeutics LLC
Sutura Therapeutics Ltd
Suzhou GenAssist Therapeutics Co Ltd
Taiho Pharmaceutical Co Ltd
Tivorsan Pharmaceuticals Inc
Tolerion Inc
Triplex Therapeutics Inc
UGISense AG
Ultragenyx Pharmaceutical Inc
Vandria SA
Vertex Pharmaceuticals Inc
Vita Therapeutics Inc
Wave Life Sciences Ltd
Zata Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Duchenne Muscular Dystrophy pipeline market?
The key targets in the Duchenne Muscular Dystrophy pipeline market are Dystrophin, Utrophin, Androgen Receptor, Glucocorticoid Receptor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Connective Tissue Growth Factor, and Growth/Differentiation Factor 8.
-
What are the key MoA in the Duchenne Muscular Dystrophy pipeline market?
The key MoA in the Duchenne Muscular Dystrophy pipeline market are Dystrophin Activator, Utrophin Activator, Glucocorticoid Receptor Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Androgen Receptor Agonist, Connective Tissue Growth Factor Inhibitor, and Growth/Differentiation Factor 8 Inhibitor.
-
What are the key RoA in the Duchenne Muscular Dystrophy pipeline market?
The key RoA in the Duchenne Muscular Dystrophy pipeline market are oral, intravenous, subcutaneous, parenteral, inhalational, intramuscular, intracoronary, intrathecal, intravascular, ophthalmic, and topical.
-
What are the key molecule types in the Duchenne Muscular Dystrophy pipeline market?
The key molecule types in the Duchenne Muscular Dystrophy pipeline market are small molecule, antisense oligonucleotide, gene therapy, cell therapy, oligonucleotide, monoclonal antibody conjugated, recombinant protein, synthetic peptide, fusion protein, gene-modified cell therapy, monoclonal antibody, protein, antisense RNAI oligonucleotide, and biologic.
-
What are the key companies in the Duchenne Muscular Dystrophy pipeline market?
The key companies in the Duchenne Muscular Dystrophy pipeline market are Sarepta Therapeutics Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, NS Pharma Inc, Avidity Biosciences Inc, Nippon Shinyaku Co Ltd, Pepgen Ltd, and Sarcomed AB.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.